Concepedia

Author

Daniel F. Ortwine

Pfizer (United States)

Also Known As

D F Ortwine, D. F. ORTWINE, D. F. Ortwine, D. ORTWINE, D. Ortwine, D.F. Ortwine, Dan F. Ortwine, Daniel F Ortwine, Daniel F. Ortwine, Daniel Ortwine

120

Publications

4.7K

Citations

40

H-Index

83

Concepts

All Affiliations

Pfizer (United States)WuXi AppTec (China)Xenon Pharmaceuticals (Canada)Gene Therapy LaboratoryWarde Medical Laboratory
DF

About

Daniel F. Ortwine is an author at Pfizer (United States) specializing in medicine, drug discovery, and pharmacology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

29

45

2.5K

2

Natural Sciences

22

27

1.6K

3

Engineering

5

5

121

4

Allergy

2

2

84

5

Health Sciences

1

1

30

Daniel F. Ortwine

×

77

Publications

4.6K

Citations

39

H-Index

YearCitations

Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability

Benjamin Lauffer, Robert Mintzer, Rina Fong,

Journal of Biological Chemistry

2013

400

Structural basis of Nav1.7 inhibition by an isoform-selective small-molecule antagonist

Shivani Ahuja, Susmith Mukund, Lunbin Deng,

Science

2015

322

Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton’s Tyrosine Kinase Inhibitor in Early Clinical Development

James J. Crawford, Adam R. Johnson, Dinah Misner,

Journal of Medicinal Chemistry

2018

240

Discovery and Characterization of a Novel Inhibitor of Matrix Metalloprotease-13 That Reduces Cartilage Damage in Vivo without Joint Fibroplasia Side Effects

Adam R. Johnson, A.G. Pavlovsky, Daniel F. Ortwine,

Journal of Biological Chemistry

2007

209

Inhibitors of cholesterol biosynthesis. 3. Tetrahydro-4-hydroxy-6-[2-(1H-pyrrol-1-yl)ethyl]-2H-pyran 2-one inhibitors of HMG-CoA reductase. 2. Effects of introducing substituents at positions three and four of the pyrrole nucleus

Bruce D. Roth, C. John Blankley, Alexander Chucholowski,

Journal of Medicinal Chemistry

1991

183

Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations

Adam R. Johnson, Pawan Bir Kohli, Arna Katewa,

ACS Chemical Biology

2016

132

Novel Series of Achiral, Low Molecular Weight, and Potent HIV-1 Protease Inhibitors

J. V. N. Vara Prasad, Kimberly S. Para, Elizabeth A. Lunney,

Journal of the American Chemical Society

1994

131

GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER+ Breast Cancer

Jun Liang, Robert A. Blake, Jae H. Chang,

Journal of Medicinal Chemistry

2021

130

Substituted 2-Benzothiazolamines as Sodium Flux Inhibitors: Quantitative Structure-Activity Relationships and Anticonvulsant Activity

Sheryl J. Hays, Michael J. Rice, Daniel F. Ortwine,

Journal of Pharmaceutical Sciences

1994

107

4-Phenylpyrrolo[3,4-<i>c</i>]carbazole-1,3(2<i>H</i>,6<i>H</i>)-dione Inhibitors of the Checkpoint Kinase Wee1. Structure−Activity Relationships for Chromophore Modification and Phenyl Ring Substitution

Brian D. Palmer, Andrew M. Thompson, R J Booth,

Journal of Medicinal Chemistry

2006

107

Page 1